SEATTLE — Sept. 21, 2020 — Scientists at Fred Hutchinson Cancer Research Center believe they’ve found a better of use of mobile technology to help adult cigarette smokers quit.
In a large clinical trial published in JAMA Internal Medicine, a team led by Dr. Jonathan Bricker, a professor in Fred Hutch’s Public Health Sciences Division, tested the efficacy of the new smartphone app iCanQuit against the National Cancer Institute’s QuitGuide. iCanQuit is based on acceptance and commitment therapy, or ACT, and QuitGuide is based on U.S. clinical practice guidelines.
While apps to quit smoking have been downloaded over 33 million times, there has been little proof they actually work. Using a rigorous double-blind, randomized clinical trial involving over 2,400 adult smokers throughout the U.S., the researchers found the iCanQuit app to be nearly 1 1/2 times more effective than QuitGuide in helping smokers quit after 12 months. Based on their findings, Bricker’s team suggests that for every 100,000 smokers reached with iCanQuit, 28,000 would quit smoking.
“Our study offers a new approach to quitting smoking,” said Bricker. “By deploying ACT-based methods that focus on acceptance of smoking triggers instead of avoidance of smoking triggers, we believe iCanQuit can help more smokers kick the habit and thereby reduce premature deaths.”
According to the World Health Organization, “smokers are at higher risk of developing severe COVID-19 outcomes and death.” Smoking and tobacco use is the leading cause of preventable death, killing over 8 million people per year. About 80% of lung cancer deaths result from smoking, and the American Cancer Society expects over 135,000 lung cancer deaths in the U.S. this year.
“Prevention is the best strategy to reduce cancer’s burden and save lives,” said Brianna Sullivan, project manager of Bricker’s team and a study co-author. “By combining Fred Hutch’s scientific expertise with effective and user-friendly technology, we’re providing smokers the tools needed to live healthier, longer and more vital lives.”
Android users can download the iCanQuit app via the Google Play store and iOS device users can download it via the App store. Passcodes to open the app are available by emailing [email protected]
The National Cancer Institute (grant number R01CA192849) funded this study but had no role in its design or conduct. Bricker reported receiving grants from the NCI during the conduct of the study, serving on the scientific advisory board for Chrono Therapeutics and receiving personal fees from Chrono outside the submitted work. Fred Hutch applied for a U.S. patent that pertains to the content of the iCanQuit app. 2Morrow Inc., a Kirkland, Washington-based software company, licensed this technology from Fred Hutch. Bricker had no personal financial relationships with this patent application, the licensing agreement or 2Morrow Inc. Co-author Kristin Mull reported receiving grants from the National Cancer Institute during the conduct of the study. Co-author Dr. Jaimee Heffner reported receiving nonfinancial support from Pfizer Inc. outside the submitted work. None of the authors has a financial relationship with the iCanQuit app and thus will not receive any compensation when it becomes publicly available.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.